抗发炎治疗药与市场:标的、技术、市场、策略、预测

已开发国家的平均寿命延长，随着人口高龄化，慢性疼痛及急性疼痛的发生率关联的罹患率增加，对患者与其家族来说作为QOL问题的疼痛管理变得更受到重视。

本报告提供抗发炎治疗药的市场调查，发炎性疾病概要，治疗标的，法律制度，市场影响因素的分析，市场规模的变化、预测，市场占有率，参与企业的简介等资料。

目录

摘要整理

发炎途径

发炎途径标的连锁

细胞激素

• 白细胞介素6(IL-6)
• 白细胞介素IL-6R
• 白细胞介素-21(IL-21)
• 白细胞介素-21R(IL-21R)
• 白细胞介素-23(IL-23)
• 白细胞介素-23R(IL-23R)
• 白细胞介素-17A(IL-17A)
• 白细胞介素-17C(IL-17C)
• 白细胞介素17A/17F
• 白细胞介素-17RA(IL-17RA)
• 白细胞介素17
• 白细胞介素-22(IL-22)

Janus激酶/蛋白酪氨酸激酶抑制剂

讯号传达蛋白质

• 转印的讯号转换器&活化剂

转化生长因子-βRI/RII(TGF-βRI/RII)

视黄酸相关孤儿受体RORyt

市场的状况

市场规模

竞争情形

免疫介质市场评估

• 支援可能市场
• 竞争情形

市场参与企业的简介

Mediating the Inflammatory Cascade

The influence of immune mediators on inflammatory diseases has put the immune mediated therapeutics at the center of inflammatory disease treatment and management. The result is a growing list of approved and development-stage drugs designed to inhibit at least one of the fifteen pathway targets that drive the transcription and secretion of inflammatory cytokines into the extracellular space where they impact patient morbidity and inflammatory disease burden. The competitive landscape now includes more than two dozen drug developers. As this marketspace has evolved, the prime product opportunities, which we define as the drugability of individual pathway targets factored by the inverse of the number of competing drugs and late-stage candidates, has been shrinking. The distribution of therapeutic products in this segment varies across pathway elements, with 84 percent targeting signaling proteins and ligands, and receptors and transcription factors accounting for 8 percent each.

Targeting Key Inflammatory Pathways:

The identification of key immune mechanisms as causative for human inflammatory disease has led to the approval and rapid development of novel therapeutic agents.

Monoclonal antibodies to a variety of cytokines and cytokine receptors and small-molecule inhibitors of RORyt and JAKs are changing the therapeutic landscape, with three dozen distinct products now approved or in clinical development.

Humanized monoclonal antibodies to both IL-17 and IL-17RA are enabling improved outcomes for moderate to severe psoriasis as well as psoriatic arthritis.

What You Will Learn:

• What are the immune factors that are responsible for immune mediated inflammatory Diseases?

• What are the inflammatory-mediated ligands, receptors, signaling proteins and transcription factors that represent druggable targets?

• What are the major factors driving the high level of development activity in immune mediated inflammatory diseases?

• What is the size of the market today, who are the market share leaders?

• What will be the effects of competing pathway solutions for the same indication and how will this dynamic impact revenue forecasts over the next four years?

• What are the significant economic, technology, and regulatory factors affecting the market for immune therapeutics?

Table of Contents

Executive Summary

Inflammatory Pathways

Inflammatory Pathway Cascade Targets

Cytokines

• Interleukin 6 (IL-6)
• Interleukin IL-6R

• Interleukin-21 (IL-21)
• Interleukin-21R (IL-21R)
• Interleukin-23 (IL-23)

• Interleukin-23R (IL-23R)
• Interleukin-17A (IL-17A)
• Interleukin-17C (IL-17C)

• Interleukin 17A/17F
• Interleukin-17RA (IL-17RA)
• Interleukin 17
• Interleukin-22 (IL-22)

Janus Kinase/Tyrosine Kinase Inhibitors

Signaling Proteins

• Signal Transducer & Activator of Transcription

Transforming Growth Factor-β RI/RII (TGF-β RI/RII)

Retinoic acid-related orphan receptor RORyt

Market Status

Market Size

Competitive Landscape

Immune Mediated Market Assessment

• Addressable Market
• Competitive Landscape

Profiles of Market Participants